AAO 2023: Promising outcomes from IOL implantation following radial keratotomy

News
Article

Data from the study, presented at the 2023 American Academy of Ophthalmology meeting in San Francisco, support the implantation of the LAL in eyes that had undergone a previous RK

An intraocular lens, balanced on a finger. Image credit: ©Nino – stock.adobe.com

Investigators studied the effect of light-adjustable lens in outcomes for patients with previous RK. Image credit: ©Nino – stock.adobe.com

Tanner J. Ferguson, MD, and colleagues from Vance Thompson Vision in Sioux Falls, SD, reported favorable outcomes regarding the visual and refractive outcomes with the Light-Adjustable Lens (LAL) (RxSight) in patients who had previously undergone radial keratotomies (RKs) with implantation of this lens after cataract surgery.

The case series included patients with history of 4-cut, 8-cut, and 16-cut RKs. The authors highlight the value of the adjustable nature of the LAL in patients with prior RK, a population that characteristically has reduced accuracy of IOL power calculations.

Ferguson reported the results at the 2023 American Academy of Ophthalmology meeting in San Francisco.

The investigators undertook a retrospective study of patients with a previous RK implanted with the LAL. In this series, they included eyes with a plano target (0.00 diopter [D]) before their final lock-in and excluded eyes with concomitant ocular pathologies that limited the corrected distance visual acuity (CDVA). The primary outcome measures included the percentage of eyes achieving a monocular uncorrected DVA (UDVA) of 20/x or better and the % of eyes within ±0.25, ±0.5, and ±1.00 D of target.

Ferguson and colleagues included 44 eyes from 34 patients in the study. They reported the following results: the monocular UDVA was 20/20 or better in 66% of eyes, 20/25 or better in 75% of eyes, and 20/30 or better in 95% of eyes 1 month after lock-in following a series of light adjustments. With emmetropia as the target, 73% of eyes were within ±0.5 D, and 93% were within ±1.00 D of that target. The MRSE was 0.4 ± 0.4 D. The mean time following implantation of the LALs to the final lock-in procedure was 9.2 ± 3.1 weeks.

The authors concluded, “The visual and refractive outcomes in this study support the implantation of the LAL in eyes that had undergone a previous RK. The postoperative adjustability of the LAL affords improved outcomes for cataract surgery in these eyes.”

Ferguson also added, “These outcomes highlight the improved visual and refractive outcomes using the LAL in post-RK eyes, but patient selection and counseling remain important in these patients as the pre-existing higher-order aberrations may limit image quality and it is important to closely evaluate the degree of irregular astigmatism before surgery.”

In addition to Ferguson, the other co-authors included Marlee Jones, BS; Daniel Terveen, MD; Brent A. Kramer, MD; Vance M. Thompson, MD; and John P. Berdahl, MD

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.